Could U.S./EU Trade Pact Let Pharma Fight EU Drug Cost Controls In Court?
This article was originally published in The Pink Sheet Daily
Executive Summary
As the European Union and the U.S. reopen talks over the Transatlantic Trade and Investment Partnership (TTIP), opponents warn its so-called Investor-State Dispute Settlement mechanism could be exploited by pharmaceutical groups, undermining efforts by member states to control their drug spending.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.